Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
MESA LABORATORIES INC /CO/
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-81.6% vs price
Base Case (Median)
-64.6% vs price
Bull Case (75th pct.)
-53.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $68.72 | -46.5% | High (40%) |
| PE Comparable | $22.19 | -82.7% | Medium (25%) |
| Growth Trajectory DCF | $45.43 | -64.6% | Medium (20%) |
| Graham Number | $25.09 | -80.5% | Low (10%) |
| EV/EBITDA | $52.14 | -59.4% | Medium (20%) |
| EV/FCF | $176.69 | 37.5% | Medium (20%) |
| Earnings Power Value | $9.79 | -92.4% | Medium (50%) |
Based on 7 out of 7 methods, MLAB appears overvalued at the current price of $128.50. The base case fair value of $45.43 implies 64.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.